中国药物评价2025，Vol.42Issue(2)：126-129,4.
瑞马唑仑联合舒芬太尼用于无痛胃镜检查中抑制呛咳反应及优化镇静效果的临床研究分析
Remimazolam-Sufentanil Combination for Cough Suppression and Optimal Sedation in Painless Gastroscopy
张彦杰 1喻静 1单立刚1
作者信息
- 1. 厦门医学院附属第二医院,福建厦门 361000
- 折叠
摘要
Abstract
Objective:To investigate the application effect of remimazolam combined with sufentanil in painless gastroscopy,with a fo-cus on analyzing its role in reducing coughing and improving sedation efficacy.Methods:A retrospective analysis was performed on the data of patients who underwent painless gastroscopy in our hospital from January 2022 to December 2023.A total of 120 patients were included after screening.Using the principle of random grouping,patients sedated with remimazolam combined with sufentanil were set as the observation group(60 cases),and those sedated with propofol combined with sufentanil were set as the control group(60 cases).Coughing during the examination,sedation efficacy,vital signs,and safety indicators such as respiratory depression were compared between the two groups.Results:There were no statistically significant differences in baseline data(age,gender,BMI,ASA grade)between the two groups(P＞0.05),indicating comparability.The anesthesia onset time and recovery time in the observation group were shorter than those in the control group(P＜0.05).During scope insertion and withdrawal,the fluctuations in mean arterial pressure(MAP)and heart rate(HR)in the observation group were smaller and maintained stable levels(P＜0.05).The incidence of coughing in the observation group was significantly lower than that in the control group(P＜0.05).Severe respiratory depression(SpO2＜90％)did not occur in either group.Conclusion:Remimazolam combined with sufentanil in painless gastroscopy can effectively reduce coug-hing,improve sedation quality,provide better hemodynamic stability,and has good safety.关键词
瑞马唑仑/舒芬太尼/无痛胃镜/呛咳/镇静Key words
Remimazolam/Sufentanil/Painless gastroscopy/Coughing/Sedation分类
药学引用本文复制引用
张彦杰,喻静,单立刚..瑞马唑仑联合舒芬太尼用于无痛胃镜检查中抑制呛咳反应及优化镇静效果的临床研究分析[J].中国药物评价,2025,42(2):126-129,4.
